VolitionRX Ltd. ( (VNRX) ) has released its Q3 earnings. Here is a breakdown of the information VolitionRX Ltd. presented to its investors.

Research indicates that cannabis use causes cellular damage that increases the risk of highly cancerous tumors by disrupting ...

Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China ...

Researchers from The University of Western Australia looked at evidence across the board on cannabis use and said the ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

Cell-free DNA can be used for non-invasive cancer detection and disease monitoring to enhance personalized medicine.

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

A "deep learning" artificial intelligence model developed at Washington State University can identify pathology, or signs of disease, in images of animal and human tissue much faster, and often more ...

A 'deep learning' artificial intelligence model can identify pathology, or signs of disease, in images of animal and human tissue much faster, and often more accurately, than people. The development ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of 2024. Volition management ...

A deep learning artificial intelligence model developed at Washington State University can identify pathology, or signs of ...